Toshikazu Takeda1, Amy L Tin2, Renato B Corradi1, Maha Mamoor1, Nicole E Benfante1, Daniel D Sjoberg2, Peter T Scardino3, James A Eastham3, Samson W Fine4, Karim A Touijer5. 1. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Urology, Weill Cornell Medical College, New York, NY, USA. 4. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Urology, Weill Cornell Medical College, New York, NY, USA. Electronic address: touijerk@mskcc.org.
Abstract
In men who do not respond to initial radiation therapy, accurate knowledge of the site of cancer recurrence or persistence is necessary to understand treatment failure. We evaluated the pathologic characteristics of recurrent/persistent prostate cancer with tumor maps from the whole-mount slides of salvage radical prostatectomies performed between 2000 and 2014. Of 216 consecutive patients, detailed tumor maps were available for 77. Sixty-nine patients (90%) were found to have tumor in the apex, of which 46% occurred in the most apical 3mm. Fifty-three patients (69%) had tumors at a distance of ≤5mm from the urethra. Five patients had tumor directly involving the urethra, all of whom had urethral invasion at the apex. Seminal vesicle involvement was seen in 32 patients (42%), two of whom had tumor only in the seminal vesicles. Sixty-two patients (81%) had tumors in the distal apex, periurethral area, or seminal vesicles, that is, areas that are not routinely biopsied. Targeting these areas could improve the accuracy of biopsy when cancer recurrence is suspected. PATIENT SUMMARY: When recurrence is suspected, clinicians should include biopsy of the distal apex, areas surrounding the urethra, and seminal vesicles. This information will help tailor successful salvage treatments.
In men who do not respond to initial radiation therapy, accurate knowledge of the site of cancer recurrence or persistence is necessary to understand treatment failure. We evaluated the pathologic characteristics of recurrent/persistent prostate cancer with tumor maps from the whole-mount slides of salvage radical prostatectomies performed between 2000 and 2014. Of 216 consecutive patients, detailed tumor maps were available for 77. Sixty-nine patients (90%) were found to have tumor in the apex, of which 46% occurred in the most apical 3mm. Fifty-three patients (69%) had tumors at a distance of ≤5mm from the urethra. Five patients had tumor directly involving the urethra, all of whom had urethral invasion at the apex. Seminal vesicle involvement was seen in 32 patients (42%), two of whom had tumor only in the seminal vesicles. Sixty-two patients (81%) had tumors in the distal apex, periurethral area, or seminal vesicles, that is, areas that are not routinely biopsied. Targeting these areas could improve the accuracy of biopsy when cancer recurrence is suspected. PATIENT SUMMARY: When recurrence is suspected, clinicians should include biopsy of the distal apex, areas surrounding the urethra, and seminal vesicles. This information will help tailor successful salvage treatments.
Authors: Daher C Chade; James Eastham; Markus Graefen; Jim C Hu; R Jeffrey Karnes; Laurence Klotz; Francesco Montorsi; Hendrik van Poppel; Peter T Scardino; Shahrokh F Shariat Journal: Eur Urol Date: 2012-01-23 Impact factor: 20.096
Authors: Sujay A Vora; William W Wong; Steven E Schild; Gary A Ezzell; Paul E Andrews; Robert G Ferrigni; Scott K Swanson Journal: J Urol Date: 2013-02-13 Impact factor: 7.450
Authors: William C Huang; Kentaro Kuroiwa; Angel M Serio; Fernando J Bianco; Samson W Fine; Bobby Shayegan; Peter T Scardino; James A Eastham Journal: J Urol Date: 2007-04 Impact factor: 7.450
Authors: Michael J Zelefsky; Deborah A Kuban; Larry B Levy; Louis Potters; David C Beyer; John C Blasko; Brian J Moran; Jay P Ciezki; Anthony L Zietman; Thomas M Pisansky; Mohamed Elshaikh; Eric M Horwitz Journal: Int J Radiat Oncol Biol Phys Date: 2006-11-02 Impact factor: 7.038
Authors: Dan Leibovici; Edmond Chiong; Louis L Pisters; Charles C Guo; John F Ward; Lizmarie Andino; Ina N Prokhorova; Patricia Troncoso Journal: J Urol Date: 2012-05-12 Impact factor: 7.450
Authors: Giancarlo Marra; Taimur T Shah; Daniele D'Agate; Alessandro Marquis; Giorgio Calleris; Luca Lunelli; Claudia Filippini; Marco Oderda; Marco Gatti; Massimo Valerio; Rafael Sanchez-Salas; Alberto Bossi; Juan Gomez-Rivas; Francesca Conte; Desiree Deandreis; Olivier Cussenot; Umberto Ricardi; Paolo Gontero Journal: Front Surg Date: 2022-06-07
Authors: Gregory T Chesnut; Amy L Tin; Arjun Sivaraman; Toshikazu Takeda; Taehyoung Lee; Jonathan Fainberg; Nicole Benfante; Daniel D Sjoberg; Hebert Alberto Vargas; Samson W Fine; Peter T Scardino; James A Eastham; Jonathan A Coleman; Karim A Touijer; Michael J Zelefsky; Behfar Ehdaie Journal: Urol Oncol Date: 2021-02-12 Impact factor: 2.954
Authors: James E Thompson; Ashwin N Sridhar; Greg Shaw; Prabhakar Rajan; Anna Mohammed; Timothy P Briggs; Senthil Nathan; John D Kelly; Prasanna Sooriakumaran Journal: BMC Urol Date: 2020-07-01 Impact factor: 2.264
Authors: Jonathan Pham; Ricky R Savjani; Stephanie M Yoon; Tiffany Yang; Yu Gao; Minsong Cao; Peng Hu; Ke Sheng; Daniel A Low; Michael Steinberg; Amar U Kishan; Yingli Yang Journal: Front Oncol Date: 2022-07-15 Impact factor: 5.738